1334 OBT698: a promising novel agonistic antibody for immuno-oncology and its potential as a cancer therapy for solid tumors

• Chantia Carroll,
• Arnima Bisht,
• Chander Peddaboina,
• Harald Haeske,
• Christian Rohlff

Affiliations

Chantia Carroll

Atreca, Inc, South San Francisco, CA, USA

Arnima Bisht

1Oxford BioTherapeutics Ltd, San Jose, CA, USA

Chander Peddaboina

1Oxford BioTherapeutics Ltd, San Jose, CA, USA

Harald Haeske

2Oxford BioTherapeutics Ltd, Abingdon, Oxfordshire, UK

Christian Rohlff

2Oxford BioTherapeutics Ltd, Abingdon, Oxfordshire, UK